Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN).

Full DD Report for ALXN

You must become a subscriber to view this report.


Recent News from (NASDAQ: ALXN)

Your Daily Scoop: Recro Proceeds, MannKind Zooms, Aduro's Publication
News in focus: REPH, MNKD Recro Pharma plans to resubmit NDA Discussion : On September 4, Recro Pharma ( REPH ) reported positive outcome of its meeting with the FDA regarding its NDA for IV meloxicam that was rejected in last May. Based on the discussion with the FDA, the comp...
Source: SeekingAlpha
Date: September, 07 2018 16:31
Alexion to Present at Morgan Stanley's 16th Annual Global Healthcare Conference
Alexion Pharmaceuticals (Nasdaq: ALXN) today announced that management will present at Morgan Stanley’s 16 th Annual Global Healthcare Conference in New York, NY on Friday, September 14, 2018 at 11:05 a.m., EDT. An audio webcast of the presentation will be available live. You can...
Source: Business Wire
Date: September, 07 2018 16:30
Apellis Pharma up 3% on encouraging APL-2 data
Apellis Pharmaceuticals ( APLS +2.5% ) is up on below-average volume on the heels of its update on a Phase 1b clinical trial, PHAROAH , evaluating APL-2 in patients with paroxysmal nocturnal hemoglobinuria (PNH) on Alexion Pharmaceuticals' ( ALXN -2.5% ) Soliris (eculizumab) who are sev...
Source: SeekingAlpha
Date: September, 04 2018 13:53
Alexion to Present at Citi's 13th Annual Biotech Conference
Alexion Pharmaceuticals (Nasdaq: ALXN) today announced that management will present at Citi’s 13 th Annual Biotech Conference in Boston, MA on Thursday, September 6, 2018 at 8:15 a.m., EDT. An audio webcast of the presentation will be available live. You can access the webcast at...
Source: Business Wire
Date: August, 29 2018 16:30
Money flow stays positive in biotechs, XBI up 6% since last week
Biotechs continue their modest rally. The SPDR S&P Biotech ETF ( XBI +1.9% ) is up albeit on below average. It has jumped  6%  since last week. More news on: SPDR Biotech ETF, Ionis Pharmaceuticals, Inc., Alnylam Pharmaceuticals, Inc., Healthcare stocks news, Stocks on the ...
Source: SeekingAlpha
Date: August, 27 2018 11:39
FDA accepts priority review of ALXN1210 as a treatment for patients with PNH in the US
The FDA has accepted for review Alexion Pharmaceuticals' (NASDAQ: ALXN ) Biologics License Application (BLA) for approval of ALXN1210, the Company’s investigational long-acting C5 complement inhibitor, for the treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH). M...
Source: SeekingAlpha
Date: August, 20 2018 07:00
FDA Accepts Priority Review of ALXN1210 as a Treatment for Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) in the US
-- EU Filing Accepted and Under Review -- Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) announced today that the U.S. Food and Drug Administration (FDA) has accepted for review the Company’s Biologics License Application (BLA) for approval of ALXN1210, the Company’s invest...
Source: Business Wire
Date: August, 20 2018 06:30
Walmart Has Become A Must-Own Stock - Cramer's Mad Money (8/16/18)
Stocks discussed on the in-depth session of Jim Cramer's Mad Money TV Program, Thursday , August 16. The market rally on Thursday will last a lot longer than the bears think. There was positivity in the market after resumed trade talks with China. Cramer said that low profile talks a...
Source: SeekingAlpha
Date: August, 17 2018 08:25
Alexion: Priced Right For Long-Term Investors
If you look at a typical brokerage summary page for Alexion Pharmaceuticals ( ALXN ), one thing you might spot is negative earnings for the past year and a negative P/E (price to earnings) ratio. Clinical development stage biotechs often run for years at a loss, generating such figures, but Al...
Source: SeekingAlpha
Date: August, 16 2018 18:41
Recent Analysis Shows Washington Real Estate Investment Trust, FirstEnergy, Alexion Pharmaceuticals, Alaska Air Group, Fortune Brands Home & Security, and Baxter International Market Influences - Renewed Outlook, Key Drivers of Growth
NEW YORK, Aug. 08, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Washington Real Estate Investment Trust (NYSE:WRE), FirstEnergy Corporati...
Source: GlobeNewswire
Date: August, 08 2018 08:15

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-09-08116.85117.27117.30115.401878,143
2018-05-17120.86121.15121.98119.69755,982
2017-06-20117.00119.05120.79116.663,592,187
2017-06-19114.51116.16117.075113.222,694,095
2017-06-16118.02113.98118.55113.134,622,346

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-12-1183,637350,49723.8624Cover
2018-12-1089,375332,38826.8888Cover
2018-12-07117,934246,29047.8842Short
2018-12-0674,890345,51521.6749Cover
2018-12-04119,314349,02634.1848Cover

* Cover Mode

Short Analysis provided by Squeeze Report. Get a complete short report on ALXN.


About Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN)

Logo for Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN)

Not available

 

Contact Information

 

 

Current Management

  • Leonard Bell / President, CEO, Secretary
  • David W. Keiser / COO

Current Share Structure

  • Market Cap: $27,334,206,450 - 05/14/2018
  • Issue and Outstanding: 222,500,663 - 04/23/2018

 


Recent Filings from (NASDAQ: ALXN)

Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: May, 11 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: April, 26 2018
Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: April, 26 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: April, 11 2018
Official notification to shareholders of matters to be brought to a vote (Proxy)
Filing Type: DEF 14AFiling Source: edgar
Filing Date: March, 28 2018
Additional proxy soliciting materials - definitive
Filing Type: DEFA14AFiling Source: edgar
Filing Date: March, 28 2018
Amendment to the SC 13G filing
Filing Type: SC 13G/AFiling Source: edgar
Filing Date: February, 14 2018
Amendment to the SC 13G filing
Filing Type: SC 13G/AFiling Source: edgar
Filing Date: February, 13 2018
Statement of beneficial ownership of common stock by certain persons
Filing Type: SC 13GFiling Source: edgar
Filing Date: February, 13 2018
Amendment to the SC 13G filing
Filing Type: SC 13G/AFiling Source: edgar
Filing Date: February, 12 2018

 

 


Daily Technical Chart for (NASDAQ: ALXN)

Daily Technical Chart for (NASDAQ: ALXN)


Stay tuned for daily updates and more on (NASDAQ: ALXN)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (NASDAQ: ALXN)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in ALXN is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of ALXN and does not buy, sell, or trade any shares of ALXN. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/